Life Science Leader Magazine

JAN 2015

The vision of Life Science Leader is to help facilitate connections and foster collaborations in pharma and med device development to get more life-saving and life-improving therapies to market in an efficient manner. Connect, Collaborate, Contribute

Issue link: https://lifescienceleadermag.epubxp.com/i/437789

Contents of this Issue

Navigation

Page 32 of 53

31 LIFESCIENCELEADER.COM JANUARY 2015 does in terms of dose response, safety profile, and lag time to efficacy, and many of these parameters are still being evalu- ated in the context of clinical trial design. In addition, while the U.S. FDA cur- rently does not regulate cost-effectiveness of medicines, there is a clear need from a consumer and payer perspective to consider the value of products; therefore, the high cost of developing biologic products requires thoughtful streamlining of drug development processes and consideration of reimbursement strategies early on in the drug-development process. General comment? Immunotherapy is an emerging and rap- idly changing area, and it is difficult to predict which approach or combination will be effective for a given cancer type. Given the promise of immunotherapy to treat a wide variety of cancers, it is impor- tant that we explore not only appropriate combinations, but also the issue of cost- effectively delivering these combinations to patients who need them. O N C O S E C M E D I C A L Developing intratumoral electroporation of a plasmid DNA construct encoding the Interleukin-12 (IL-12) protein to stimulate production of tumor-infiltrating lymphocytes (TILs) complementary to PD-1 inhibition. ROBERT H. PIERCE, M.D., Chief Scientif c Off cer (Former member of the global development team for the anti-PD-1 program [pembrolizumab] at Merck & Co.) Why combinations? Our drug-development strategy is to com- bine our IL-12 treatment with anti-PD-1 or other checkpoint inhibitors because the two mechanisms seem to work togeth- er so well. There is a "monotherapeutic fetishism" in traditional oncology; many good drugs probably would be extremely safe and have synergistic activity when combined, but they never get through development because they don't show monotherapy activity. Fortunately, intra- tumoral IL-12 electroporation has mono- therapy activity. So, how do we augment the immunogenicity of tumors? We use intratumoral electroporation to deliver IL-12, which sits at the top of a hierarchy of cytokines, which drives immunogenic- ity and potent antitumor immunity. This is not just a local ablation. With the intra- tumoral injection of IL-12, we get systemic immune responses in more than half of the treated patients, and we are also get- ting a large TIL response — the key to boosting response to anti-PD-1. Essential components? All the possible components will have to go through clinical trials. The entire clinical and regulatory community rec- ognizes that the future will bring more combination immunotherapy trials. We need to figure out means to choose ratio- nal and safe combinations and make the process more practical. Even when you have squeaky-clean molecules, regulators understandably worry about synergistic toxicities. Anti-PD-1 has a really low tox- icity profile compared to say, ipilimumab or IL-2, and with our IL-12, we haven't had a single drug-related serious adverse event. But it's fair to say, if you're having synergistic efficacy, you may also have synergistic side effects. Backbone therapy? PD-1 therapy is a straightforward story: If you look in a microscope and you see the PD-1+ TILs in the tumor nestled together with PD-L1+ tumor and macrophages, that patient will likely respond to an anti- PD-1 drug. That is a beautiful piece of biology, but the vast majority of patients do not respond to anti-PD-1 monotherapy. This is the biggest unmet medical need in immunotherapy. Narrow or wide applications? While I was at Merck, we developed an anti-PD-L1 antibody immunohistochemis- try assay, and it became immediately clear that — across the board — there exists a subpopulation of patients in most all tumor types who have the PD-L1/PD-1+ TIL "adaptive resistance" phenotype, which Copyright © 2014 PerkinElmer, Inc. 400305_03 All rights reserved. PerkinElmer ® is a registered trademark of PerkinElmer, Inc. All other trademarks are the property of their respective owners. To get high-quality drug candidates to trial sooner, your scientists need to concentrate on what they do best – the science. With OneSource® Scientifc Services, we deliver the expertise you need, helping maximize lab efciencies so everything simply works. What's more, our Instrument Check™ and Instrument Concierge™ oferings deliver individualized, white-glove services that go over and above: instrument performance checks, carrying out routine experiments, whatever's needed to improve lab productivity. OneSource Scientifc Services: Get used to a higher level of care. Download our Instrument Concierge white paper. www.perkinelmer.com/instrumentconcierge SCIENTIFIC SERVICES WITH A PERSONAL TOUCH

Articles in this issue

Links on this page

Archives of this issue

view archives of Life Science Leader Magazine - JAN 2015